Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Continues To Plot New Course In Naming Two Key Executives. But Is Independence Part Of The Plan?

This article was originally published in The Pink Sheet Daily

Executive Summary

The big biotech announces Steve Holtzman, former chairman of Infinity, as head of corporate development, with Doug Williams, former CEO of ZymoGenetics stepping in as exec VP of R&D.
Advertisement

Related Content

Biogen/Elan Submit Applications For Tysabri Label Change Ahead of Schedule
Culling The Pipeline: An Analysis Of Biogen's Discontinued Programs
Gilenya Could Surpass Avonex Market Share, Analysts Say
Biogen Idec Lays Off 13 Percent of Staff, Retrenches Around Multiple Sclerosis
Biogen Idec Lays Off 13 Percent of Staff, Retrenches Around Multiple Sclerosis
From HCV Partner To Acquirer, BMS Makes $885 M Offer for ZymoGenetics
Biogen Makes Counterintuitive Move To Tap Exelixis's Scangos As CEO
Infinity/Purdue: The Challenge of Reprising Roche/Genentech

Topics

Advertisement
UsernamePublicRestriction

Register

PS071783

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel